Infinion Biopharma Profile
Key Indicators
- Authorised Capital ₹ 17.50 Cr
as on 16-11-2024
- Paid Up Capital ₹ 10.59 Cr
as on 16-11-2024
- Company Age 7 Year, 6 Days
- Last Filing with ROC 31 Mar 2023
- Revenue 1068.79%
(FY 2023)
- Profit 3927.62%
(FY 2023)
- Ebitda 70.44%
(FY 2023)
- Net Worth 33.60%
(FY 2023)
- Total Assets 35.25%
(FY 2023)
About Infinion Biopharma
The Corporate was formerly known as Glia Biopharmaceutical Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 17.50 Cr and a paid-up capital of Rs 10.59 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Infinion Biopharma Limited India is Shivani Pathak as COMPANY SECRETARY. Narendrasinh Devda, Gautam Bali, Dinesh Singh, and Three other members serve as directors at the Company.
- CIN/LLPIN
U51909GJ2018PLC100571
- Company No.
100571
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
16 Jan 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Infinion Biopharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shivani Pathak  | Company Secretary | 09-Sep-2024 | Current |
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vishal Jain | Director | 10-Mar-2018 | Current |
| Pankaj Singh | Director | 30-Sep-2019 | Current |
| Gautam Bali | Director | 25-Jul-2018 | Current |
| Narendrasinh Devda | Whole-Time Director | 16-Jan-2018 | Current |
| Dinesh Singh | Director | 05-Jun-2021 | Current |
Govindsingh Chavda  | Director | 16-Jan-2018 | Current |
Financial Performance of Infinion Biopharma.
Infinion Biopharma Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1068.79% increase. The company also saw a substantial improvement in profitability, with a 3927.62% increase in profit. The company's net worth Soared by an impressive increase of 33.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Infinion Biopharma?
In 2023, Infinion Biopharma had a promoter holding of 76.22% and a public holding of 23.77%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Panzer Division Security & Allied Services Private LimitedActive 12 years 8 monthsGautam Bali is a mutual person
Innovate Lifesciences Private LimitedActive 4 years 11 monthsNarendrasinh Devda, Govindsingh Chavda and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Infinion Biopharma?
Unlock and access historical data on people associated with Infinion Biopharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Infinion Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Infinion Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
